Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B
Jun Liu, Patrick Budylowski, Reuben Samson, et al.
Science Advances (2022) Vol. 8, Iss. 3
Open Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

COVID-19 mRNA vaccines: Platforms and current developments
Gábor Szabó, Azita J. Mahiny, Irena Vlatkovic
Molecular Therapy (2022) Vol. 30, Iss. 5, pp. 1850-1868
Open Access | Times Cited: 194
Vaccination against SARS-CoV-2 provides low-level cross-protection against common cold coronaviruses in mouse and non-human primate animal models
Maedeh Naghibosadat, George Babuadze, Yanlong Pei, et al.
Journal of Virology (2025)
Open Access | Times Cited: 1
Delivery of mRNA for regulating functions of immune cells
Jia Shi, Mengwen Huang, Zi-Dong Lu, et al.
Journal of Controlled Release (2022) Vol. 345, pp. 494-511
Open Access | Times Cited: 42
Adjuvant physiochemistry and advanced nanotechnology for vaccine development
Hongze Ren, Wencong Jia, Yujie Xie, et al.
Chemical Society Reviews (2023) Vol. 52, Iss. 15, pp. 5172-5254
Closed Access | Times Cited: 30
Carrier-free mRNA vaccine induces robust immunity against SARS-CoV-2 in mice and non-human primates without systemic reactogenicity
Saed Abbasi, Miki Matsui-Masai, Fumihiko Yasui, et al.
Molecular Therapy (2024) Vol. 32, Iss. 5, pp. 1266-1283
Open Access | Times Cited: 12
Nanotechnology against COVID-19: Immunization, diagnostic and therapeutic studies
Akbar Hasanzadeh, Masoomeh Alamdaran, Sepideh Ahmadi, et al.
Journal of Controlled Release (2021) Vol. 336, pp. 354-374
Open Access | Times Cited: 43
An overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID-19)
Armina Alagheband Bahrami, Ali Azargoonjahromi, Samin Sadraei, et al.
Cellular & Molecular Biology Letters (2022) Vol. 27, Iss. 1
Open Access | Times Cited: 27
A potential bivalent mRNA vaccine candidate protects against both RSV and SARS-CoV-2 infections
Namei Wu, Jiachen Zhang, Yanqiong Shen, et al.
Molecular Therapy (2024) Vol. 32, Iss. 4, pp. 1033-1047
Closed Access | Times Cited: 6
A bivalent COVID-19 mRNA vaccine elicited broad immune responses and protection against Omicron subvariants infection
Jun Liu, Li Wang, Alexandra Kurtesi, et al.
npj Vaccines (2025) Vol. 10, Iss. 1
Open Access
PD-L1 siRNA incorporation into a cationic liposomal tumor mRNA vaccine enhances cytotoxic T cell activation and prevents immune evasion
Jingsheng Zhou, Yuanyuan Li, Xianghe Jiang, et al.
Materials Today Bio (2025) Vol. 31, pp. 101603-101603
Open Access
mRNA Vaccines: Design Principles, Mechanisms, and Manufacturing—Insights From COVID‐19 as a Model for Combating Infectious Diseases
Saeideh Khorshid Sokhangouy, Mohammad Amin Behzadi, Samira Rezaei, et al.
Biotechnology Journal (2025) Vol. 20, Iss. 2
Closed Access
Optimization of a panel of behavioral tests for use in containment using a golden Syrian hamster model
Rachel A. Reyna, Jordyn Walker, Ashley Viveros, et al.
Journal of Virological Methods (2025), pp. 115132-115132
Open Access
Delivery and Expression of mRNA in the Secondary Lymphoid Organs Drive Immune Responses to Lipid Nanoparticle-mRNA Vaccines after Intramuscular Injection
Asuka Takanashi, Colin W. Pouton, Hareth Al-Wassiti
Molecular Pharmaceutics (2023) Vol. 20, Iss. 8, pp. 3876-3885
Closed Access | Times Cited: 12
Host Genetic Variation Impacts SARS-CoV-2 Vaccination Response in the Diversity Outbred Mouse Population
Marta C Cruz Cisneros, Elizabeth J. Anderson, Brea K. Hampton, et al.
Vaccines (2024) Vol. 12, Iss. 1, pp. 103-103
Open Access | Times Cited: 4
Comparable safety and non-inferior immunogenicity of the SARS-CoV-2 mRNA vaccine candidate PTX-COVID19-B and BNT162b2 in a phase 2 randomized, observer-blinded study
Lawrence T. Reiter, Johann Greffrath, Bian Zidel, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 3
Extracellular vesicles versus lipid nanoparticles for the delivery of nucleic acids
Johannes Bader, Finn Brigger, Jean‐Christophe Leroux
Advanced Drug Delivery Reviews (2024), pp. 115461-115461
Open Access | Times Cited: 3
Effects of SARS-CoV-2 Omicron BA.1 Spike Mutations on T-Cell Epitopes in Mice
Yudong Wang, Busen Wang, Zhenghao Zhao, et al.
Viruses (2023) Vol. 15, Iss. 3, pp. 763-763
Open Access | Times Cited: 8
Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice
Dennis J. Horvath, Nigel Temperton, Martin Mayora‐Neto, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 8
Biomaterial-enabled therapeutic modulation of cGAS-STING signaling for enhancing antitumor immunity
Yingqi Liu, Fei Yang, Xuan Wang, et al.
Molecular Therapy (2023) Vol. 31, Iss. 7, pp. 1938-1959
Open Access | Times Cited: 7
SARS-CoV-2 Variant Pathogenesis Following Primary Infection and Reinfection in Syrian Hamsters
Jessica Plunkard, Kathleen R. Mulka, Ruifeng Zhou, et al.
mBio (2023) Vol. 14, Iss. 2
Open Access | Times Cited: 7
Protective efficacy of a universal influenza mRNA vaccine against the challenge of H1 and H5 influenza A viruses in mice
Yulei Li, Xi Wang, Xi Zeng, et al.
mLife (2023) Vol. 2, Iss. 3, pp. 308-316
Open Access | Times Cited: 7
Airway surveillance and lung viral control by memory T cells induced by COVID-19 mRNA vaccine
Brock Kingstad-Bakke, Thomas Cleven, Hailey E. Bussan, et al.
JCI Insight (2023) Vol. 8, Iss. 22
Open Access | Times Cited: 7
Phase I randomized, observer-blinded, placebo-controlled study of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B
Natalia Martín‐Orozco, Noah Vale, Alan Mihic, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 5
An Extensive Evaluation of New Federated Learning Approaches for COVID-19 Identification
Ranjit Barua, Sudipto Datta
Advances in healthcare information systems and administration book series (2023), pp. 246-257
Closed Access | Times Cited: 5
Vaccine targeting to mucosal lymphoid tissues promotes humoral immunity in the gastrointestinal tract
Ozgun Kocabiyik, Parastoo Amlashi, Anh Lina Vo, et al.
Science Advances (2024) Vol. 10, Iss. 22
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top